Journal article

Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis

Marcelo Sobral-Leite, Jelle Wesseling, Vincent THBM Smit, Heli Nevanlinna, Martine H van Miltenburg, Joyce Sanders, Ingrid Hofland, Fiona M Blows, Penny Coulson, Gazinska Patrycja, Jan HM Schellens, Rainer Fagerholm, Paivi Heikkila, Kristiina Aittomaki, Carl Blomqvist, Elena Provenzano, Hamid Raza Ali, Jonine Figueroa, Mark Sherman, Jolanta Lissowska Show all

BMC MEDICINE | BMC | Published : 2015

Abstract

BACKGROUND: Annexin A1 (ANXA1) is a protein related with the carcinogenesis process and metastasis formation in many tumors. However, little is known about the prognostic value of ANXA1 in breast cancer. The purpose of this study is to evaluate the association between ANXA1 expression, BRCA1/2 germline carriership, specific tumor subtypes and survival in breast cancer patients. METHODS: Clinical-pathological information and follow-up data were collected from nine breast cancer studies from the Breast Cancer Association Consortium (BCAC) (n = 5,752) and from one study of familial breast cancer patients with BRCA1/2 mutations (n = 107). ANXA1 expression was scored based on the percentage of im..

View full abstract

Grants

Awarded by Cancer Research UK


Awarded by Dutch Cancer Society


Awarded by Baden Wurttemberg Ministry of Science, Research and Arts, Helsinki University Central Hospital Research Fund, Academy of Finland


Awarded by NIH


Awarded by NIH Specialized Program of Research Excellence (SPORE) in Breast Cancer


Awarded by Academy of Medical Sciences (AMS)


Awarded by National Institute for Health Research


Awarded by The Francis Crick Institute


Awarded by National Breast Cancer Foundation


Awarded by Cancer Foundation Finland sr


Awarded by NATIONAL CANCER INSTITUTE


Funding Acknowledgements

Cancer Research UK (C1287/A10118, C1287/A12014, C490/A10124, C490/A10119 and C490/A16561), the UK National Institute for Health Research Biomedical Research Centre at the University of Cambridge; BIHR Biomedical Research Centre at the University of Cambridge; Dutch Cancer Society (grants NKI 2007-3839, 2009-4363; DDHK 2004-3124, DDHK 2009-4318); Baden Wurttemberg Ministry of Science, Research and Arts, Helsinki University Central Hospital Research Fund, Academy of Finland (266528), the Finnish Cancer Society, the Nordic Cancer Union and the Sigrid Juselius Foundation, Special Government Funding (FVO) of Kuopio University Hospital grants, Cancer Fund of North Savo, the Finnish Cancer Organizations, Australia National Breast Cancer Foundation, National Health and Medical Research Council (NHMRC), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, the Cancer Foundation of Western Australia, NIH grants (CA128978, CA116167, CA176785), NIH Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), the Breast Cancer Research Foundation, the David F and Margaret T Grohne Family Foundation, the Ting Tsung and Wei Fong Chao Foundation, Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA and CAPES Foundation. KAP is supported by a National Breast Cancer Foundation Practitioner Fellowship.